Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00680160 · ClinicalTrials.gov registry record · Phase 2
Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I)
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00680160 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 15 participants.
The verdict
NCT00680160, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the absorption, systemic pharmacokinetics and accumulation in the nail of AN2690 during a 28 day period of daily application of a 7.5% solution of AN2690 to all 10 toenails of up to 25 otherwise healthy adult patients with onychomycosis.
Interventions
- DRUG AN2690
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2006-04-30 |
| Est. Completion | 2007-05-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00680160
The ClinicalTrials.gov registry entry for NCT00680160 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AN2690 is the first listed.
NCT00680160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00680160 about?
NCT00680160 is a clinical study titled "Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I)". The purpose of the study is to determine the absorption, systemic pharmacokinetics and accumulation in the nail of AN2690 during a 28 day period of daily application of a 7.5% solution of AN2690 to all 10 toenails of up to 25 otherwise healthy adult patients with onychomycosis.
What is the current status of trial NCT00680160?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2006-04-30. Estimated completion is 2007-05-09.
What interventions are being tested in trial NCT00680160?
The interventions under investigation include: AN2690 (DRUG).
Who is sponsoring clinical trial NCT00680160?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.